ArticleAllergy2026
Bidirectional Associations Between Seborrheic Dermatitis and Epithelial Barrier Diseases: A Retrospective Cohort Study.
Article in Allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSeborrheic dermatitis (SD) is a common skin disease characterized by epithelial barrier breakdown. The epithelial barrier theory (EBT) implicates epithelial barrier disruption in the development of epithelial barrier diseases (EBDs). We hypothesized that SD is associated with an increased risk of EBDs and investigated the bidirectional association between SD and EBDs.
methodsRetrospective cohort study of 5,083,689 patients using a large US administrative claims database from January 1, 2016, to June 30, 2022. The mean (standard deviation) follow-up was 3.25 (1.75) years with a total follow-up of over 16 million person-years. The outcomes were a diagnosis of (i) SD after an EBD and (ii) EBD after SD, analyzed using a multivariable Cox proportional hazards model (hazard ratio [95% confidence interval]).
resultsThe risk of SD was increased after EBD diagnosis for multiple diseases, including atopic dermatitis [2.46 (2.40, 2.53)], alopecia areata [3.47 (3.24, 3.71)], contact dermatitis [1.92 (1.88, 1.96)], psoriasis [2.62 (2.54, 2.69)], rosacea [2.84 (2.78, 2.90)], hidradenitis suppurativa [1.79 (1.63, 1.97)], rhinosinusitis [1.34 (1.32, 1.35)], food allergy [1.47 (1.42, 1.54)], celiac disease [1.55 (1.43, 1.68)], ocular allergy [1.55 (1.49, 1.61)], and dry eye [1.54 (1.52, 1.56)]. The risk of EBD after SD diagnosis followed similar trends, with the largest effect estimates being psoriasis [3.52 (3.42, 3.61)], rosacea [2.85 (2.79, 2.92)], and alopecia areata [2.81 (2.61, 3.03)].
conclusionsOur results support the EBT as a shared driver of EBD pathogenesis at not only local (e.g., skin) barriers but also at non-local sites, including the respiratory, gastrointestinal, and ocular epithelial barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.